Centogene (NASDAQ:CNTG) Downgraded by Zacks Investment Research to Sell

Centogene (NASDAQ:CNTG) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report issued on Tuesday, Zacks.com reports.

According to Zacks, “Centogene is a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians and pharmaceutical companies. The Company’s goal is to bring rationality to treatment decisions and to accelerate the development of new orphan drugs by using their knowledge of the global rare disease market, including epidemiological and clinical data and innovative biomarkers. “

Several other analysts have also recently weighed in on the stock. BTIG Research increased their price target on shares of Centogene from $18.00 to $23.00 and gave the company a “buy” rating in a research note on Friday, April 24th. Robert W. Baird increased their price objective on shares of Centogene from $15.00 to $20.00 and gave the stock an “outperform” rating in a research report on Friday, April 24th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $20.00.

Shares of Centogene stock traded up $1.49 during mid-day trading on Tuesday, hitting $21.10. The stock had a trading volume of 192,900 shares, compared to its average volume of 19,947. The firm has a 50-day moving average of $18.56 and a two-hundred day moving average of $15.59. Centogene has a 12-month low of $7.80 and a 12-month high of $28.71. The company has a quick ratio of 1.79, a current ratio of 1.98 and a debt-to-equity ratio of 0.38. The firm has a market cap of $419.05 million and a P/E ratio of -14.45.

Centogene (NASDAQ:CNTG) last posted its quarterly earnings results on Monday, June 15th. The company reported ($0.43) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.10). The firm had revenue of $13.35 million for the quarter, compared to analyst estimates of $13.78 million. Sell-side analysts expect that Centogene will post -1.74 earnings per share for the current year.

Institutional investors have recently added to or reduced their stakes in the business. Wells Fargo & Company MN lifted its holdings in Centogene by 1,055.3% during the 1st quarter. Wells Fargo & Company MN now owns 1,756 shares of the company’s stock worth $35,000 after buying an additional 1,604 shares in the last quarter. UBS Group AG acquired a new stake in Centogene during the 4th quarter worth approximately $38,000. JPMorgan Chase & Co. lifted its holdings in Centogene by 23.7% during the 1st quarter. JPMorgan Chase & Co. now owns 3,054 shares of the company’s stock worth $61,000 after buying an additional 586 shares in the last quarter. Meeder Asset Management Inc. acquired a new stake in Centogene during the 1st quarter worth approximately $67,000. Finally, New York State Common Retirement Fund acquired a new stake in Centogene during the 4th quarter worth approximately $97,000. Institutional investors own 8.35% of the company’s stock.

About Centogene

Centogene B.V. operates as a commercial-stage rare disease company worldwide. It focuses on transforming clinical and genetic data into medical solutions for patients, physicians, and pharmaceutical companies. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs.

Read More: How are Outstanding Shares Different from Authorized Shares?

Get a free copy of the Zacks research report on Centogene (CNTG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Centogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centogene and related companies with MarketBeat.com's FREE daily email newsletter.